Skip to content
Review Open access

CAR-T Cell Therapy Combined with PD-1 Inhibitors in Cancer: Synergistic Antitumor Mechanisms, Clinical Progress, and Future Perspective

Oct 2026 · Theoretical and Natural Science · 0 citations

TL;DR

Data from preclinical models and clinical trials indicate that PD-1 inhibition helps exhausted CAR-T cells recover function, shifts the TME away from an immunosuppressive state, and supports epitope spreading; together these effects strengthen antitumor activity and may lower relapse rates.

Abstract

Among the most transformative advances in cancer immunotherapy, chimeric antigen receptor (CAR)-T cell therapy and inhibitors of programmed cell death protein 1 (PD-1) stand out, yet each approach carries its own weaknesses. CAR-T therapy produces dramatic responses in hematologic malignancies, although T-cell exhaustion, antigen escape, and an immunosuppressive tumor microenvironment (TME) frequently curtail its durability. In contrast, PD-1 monotherapy acts across a broad range of tumors and can yield long-lasting responses, but primary and acquired resistance leave most patients without benefit. Here we examine the mechanistic basis and potential synergy of pairing CAR-T cells with PD-1 blockade. Data from preclinical models and clinical trials indicate that PD-1 inhibition helps exhausted CAR-T cells recover function, shifts the TME away from an immunosuppressive state, and supports epitope spreading; together these effects strengthen antitumor activity and may lower relapse rates. Feasibility and encouraging responses have been reported in both blood cancers and solid tumors, but several obstacles persist: treatment schedules are not standardized, toxicities may overlap, solid-tumor responses remain modest because resistance is multifactorial, and outcomes vary markedly from one patient to another. This review concludes by outlining the current evidence, dissecting the synergistic mechanisms, and highlighting the challenges ahead, and argues that refined regimens, validated predictive biomarkers, and individualized strategies will be essential before this combination can reach its full potential.

Read PDF

Similar papers

Open access Oct 2026

CAR-T Therapy in Leukemia: Limitations and Prospects

In the broad field of cancer management via immunotherapy, chimeric antigen receptor T-cell therapy (CAR-T therapy), commonly known as CAR-T therapy, has become a game-changing approach, particularly for patients with relapsed or refractory lymphoma. Using genetic engineering, a patient's T cells can be genetically mod...

Li-Jie Yan · 0 citations
Review Open access Oct 2026

Combination Therapies of CAR-T Cells for Glioblastoma: Current Advances, Challenges, and Future Perspectives

Glioblastoma multiforme (GBM) is one of the most aggressive malignant brain tumours among adults. Since many conventional therapies have demonstrated limited advancement, an emerging immunotherapy called Chimeric Antigen Receptor T-cell therapy (CAR-T therapy) is gradually becoming the hope for transforming GBM treatme...

Juan-Ya Zhou · 0 citations
Review Open access Sep 2026

Synergistic Antitumor Activity of Personalized mRNA Neoantigen Vaccines and PD-1/PD-L1 Inhibitor in Solid Tumors

Immunotherapy for cancer now represents a breakthrough in treatment of solid tumors. However, the clinical efficacy of immune checkpoint inhibitors is still limited by insufficient tumor-specific immune activation and multiple immune escape mechanisms. Personalized mRNA vaccines based on neoantigens offer an encouragin...

Zhen-Li He · 0 citations
Review Open access Sep 2026

The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment

Current challenges in solid tumour treatment are examined through evidence from clinical trials, highlighting key obstacles such as antigen heterogeneity, the immunosuppressive tumour microenvironment, poor cellular trafficking, and treatment-related failures that have informed the development of next-generation CAR co...

A. Justiz-Vaillant, Sachin Soodeen, Rodolfo Arozarena-Fundora et al. · 3 citations
Review Open access Sep 2026

The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy

Evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods is highlighted, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration.

Seong-Ah Shin, Minji Kim, Moonsu Kim et al. · 0 citations
Review Open access Oct 2026

The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is associated with a poor prognosis, and the efficacy of conventional therapies (chemotherapy, radiotherapy, and surgery) remains limited. The advent of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has substantially altered the treatment paradigm for E...

Ru-Yan Li, Zi-Hao Heng, Xi Cheng · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.